Literature DB >> 11687500

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

R Katso1, K Okkenhaug, K Ahmadi, S White, J Timms, M D Waterfield.   

Abstract

The phosphoinositide 3-kinase (PI3K) family of enzymes is recruited upon growth factor receptor activation and produces 3' phosphoinositide lipids. The lipid products of PI3K act as second messengers by binding to and activating diverse cellular target proteins. These events constitute the start of a complex signaling cascade, which ultimately results in the mediation of cellular activities such as proliferation, differentiation, chemotaxis, survival, trafficking, and glucose homeostasis. Therefore, PI3Ks play a central role in many cellular functions. The factors that determine which cellular function is mediated are complex and may be partly attributed to the diversity that exists at each level of the PI3K signaling cascade, such as the type of stimulus, the isoform of PI3K, or the nature of the second messenger lipids. Numerous studies have helped to elucidate some of the key factors that determine cell fate in the context of PI3K signaling. For example, the past two years has seen the publication of many transgenic and knockout mouse studies where either PI3K or its signaling components are deregulated. These models have helped to build a picture of the role of PI3K in physiology and indeed there have been a number of surprises. This review uses such models as a framework to build a profile of PI3K function within both the cell and the organism and focuses, in particular, on the role of PI3K in cell regulation, immunity, and development. The evidence for the role of deregulated PI3K signaling in diseases such as cancer and diabetes is reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687500     DOI: 10.1146/annurev.cellbio.17.1.615

Source DB:  PubMed          Journal:  Annu Rev Cell Dev Biol        ISSN: 1081-0706            Impact factor:   13.827


  363 in total

1.  The α-isoform of class II phosphoinositide 3-kinase is necessary for the activation of ERK but not Akt/PKB.

Authors:  Z G Cui; N Y Hong; H K Kang; D H Lee; Y K Lee; D B Park
Journal:  Mol Cell Biochem       Date:  2010-10-06       Impact factor: 3.396

2.  Phosphatidylinositol 3,4,5-trisphosphate activity probes for the labeling and proteomic characterization of protein binding partners.

Authors:  Meng M Rowland; Heidi E Bostic; Denghuang Gong; Anna E Speers; Nathan Lucas; Wonhwa Cho; Benjamin F Cravatt; Michael D Best
Journal:  Biochemistry       Date:  2011-11-30       Impact factor: 3.162

3.  Inducible shRNA expression for application in a prostate cancer mouse model.

Authors:  Frank Czauderna; Ansgar Santel; Michael Hinz; Melanie Fechtner; Birgit Durieux; Gerald Fisch; Frauke Leenders; Wolfgang Arnold; Klaus Giese; Anke Klippel; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 4.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

5.  Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

Authors:  Sida Shen; Xiangyu He; Zheng Yang; Liang Zhang; Yingtao Liu; Zhiyuan Zhang; Weiwei Wang; Wei Liu; Yufeng Li; Dong Huang; Kai Sun; Xiaojing Ni; Xu Yang; Xinxin Chu; Yumin Cui; Qiang Lv; Jiong Lan; Fusheng Zhou
Journal:  ACS Med Chem Lett       Date:  2018-06-25       Impact factor: 4.345

6.  Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Authors:  Brittany Knick Ragon; Olatoyosi Odenike; Maria R Baer; Wendy Stock; Gautam Borthakur; Keyur Patel; Lina Han; Helen Chen; Helen Ma; Loren Joseph; Yang Zhao; Keith Baggerly; Marina Konopleva; Nitin Jain
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-26

7.  Metastatic Renal Cancer: What Role for Everolimus?

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Clin Med Rev Oncol       Date:  2010-02-18

8.  Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells.

Authors:  H Sheng; J Shao; C M Townsend; B M Evers
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation.

Authors:  Teresa G Tessner; Filipe Muhale; Terrence E Riehl; Shrikant Anant; William F Stenson
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

10.  Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.

Authors:  Yvette M Carter; Selvi Kunnimalaiyaan; Herbert Chen; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.